Approaching the ideal selective estrogen receptor modulator for prevention and treatment of postmenopausal osteoporosis; Exenatide LAR: A sustained-release formulation of exenatide for the treatment of type 2 diabetes; and Agents in late-stage development for renal diseases

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Formulary Digital Edition February 2010

Newsletter